Table 1.
Baseline characteristics
| Total (n = 74) | NLR < 2.58 at T2 (n = 30) | NLR ≥ 2.58 at T2 (n = 44) | p Value | |
|---|---|---|---|---|
| Age (years), mean ± SD | 50 ± 12 | 53 ± 12 | 49 ± 11 | .18 |
| BSA (m2), median (IQR) | 1.69 (1.59–1.84) | 1.71 (1.60–1.79) | 1.69 (1.57–1.90) | .92 |
| Medical history | ||||
| Hypertension, n (%) | 14 (18.9) | 9 (30.0) | 5 (11.4) | .04 |
| Diabetes mellitus, n (%) | 5 (6.8) | 4 (13.3) | 1 (2.3) | .15 |
| Hypercholesterolemia, n (%) | 9 (12.2) | 5 (16.7) | 4 (9.1) | .32 |
| Smoking (current or past), n (%) | 16 (21.6) | 4 (13.3) | 12 (27.3) | .15 |
| Concomitant anticancer therapy | ||||
| Paclitaxel, n (%) | 71 (96) | 27 (90) | 44 (100) | .06 |
| Carboplatin, n (%) | 10 (14) | 3 (10) | 7 (16) | .46 |
| Trastuzumab, n (%) | 16 (22) | 5 (17) | 11 (25) | .39 |
| Left chest radiation, n (%) | 32 (43) | 11 (37) | 21 (48) | .35 |
| Medications | ||||
| Beta‐blockers, n (%) | 3 (4.1) | 2 (6.7) | 1 (2.3) | .56 |
| ACEI/ARB, n (%) | 13 (17.6) | 7 (23.3) | 6 (13.6) | .28 |
| ACEI/ARB/beta‐blockers, n (%) | 13 (17.6) | 7 (23.3) | 6 (13.6) | .28 |
| Statins, n (%) | 10 (13.5) | 5 (16.7) | 5 (11.4) | .51 |
| Antiaggregation, n (%) | 5 (6.8) | 1 (3.3) | 4 (9.1) | .64 |
| Laboratory data at T1 | ||||
| Hemoglobin (g/dl), mean ± SD | 12.9 ± 1.0 | 12.8 ± 1.0 | 12.9 ± 1.0 | .61 |
| White blood cell count (109/L), mean ± SD | 6.7 ± 2.4 | 6.3 ± 2.1 | 7.1 ± 2.5 | .61 |
| Platelet count (109/L), median (IQR) | 257 (209–297) | 259(215–305) | 251(201–297) | .42 |
| Creatinine (mg/dl), mean ± SD | 0.68 ± 0.15 | 0.69 ± 0.12 | 0.66 ± 0.15 | .31 |
| Laboratory data at T2 | ||||
| Hemoglobin (g/dl), mean ± SD | 11.3 ± 1.2 | 11.2 ± 1.2 | 11.4 ± 1.2 | .58 |
| White blood cell count (109/L), median (IQR) | 5.9 (3.8–7.9) | 4.0 (2.9–5.9) | 7.1 (5.4–9.5) | <.001 |
| Platelet count (109/L), median (IQR) | 226 (186–298) | 258 (184–324) | 221 (190–282) | .37 |
| Creatinine (mg/dl), mean ± SD | 0.64 ± 0.17 | 0.65 ± 0.15 | 0.63 ± 0.17 | .67 |
Note: Bold values are significant p < .05.
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BB, beta‐blockers; BSA, body surface area; IQR, interquartile range; NLR, neutrophil‐to‐lymphocyte ratio; SD, standard deviation; T1, baseline before doxorubicin therapy; T2, during doxorubicin exposure.